Risiken und Nebenwirkungen von Immunsuppressiva in der Therapie chronisch entzündlicher Darmerkrankungen

• Literatur

• 1 Preiß JC, Bokemeyer B, Buhr HJ et al. Updated German clinical practice guideline on „Diagnosis and treatment of Crohn’s disease” 2014. Z Gastroenterol 2014; 52: 1431-1484
• 2 Dignass A, Preiss JC, Aust DE et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 2011; 49: 1276-1341
• 3 Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010; 4: 28-62
• 4 Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030
• 5 Schmidt C, Herrlinger K, Siegmund B et al. [Azathioprine in Crohn‘s disease therapy – guidance against the background of recent studies]. Z Gastroenterol 2014; 52: 1423-1430
• 6 Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-1395
• 7 Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400
• 8 Teml A, Schaeffeler E, Herrlinger KR et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007; 46: 187-208
• 9 Hoentjen F, Seinen ML, Hanauer SB et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 363-369
• 10 Schaeffeler E, Fischer C, Brockmeier D et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-417
• 11 Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489
• 12 Avallone EV, Pica R, Cassieri C et al. Azathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects. Eur Rev Med Pharmacol Sci 2014; 18: 165-170
• 13 Present DH, Meltzer SJ, Krumholz MP et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-649
• 14 Haber CJ, Meltzer SJ, Present DH et al. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986; 91: 982-986
• 15 Heikius B, Niemelä S, Lehtola J et al. Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease. Am J Gastroenterol 1999; 94: 1062-1069
• 16 Wickramasinghe SN, Dodsworth H, Rault RM et al. Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation 1974; 18: 443-446
• 17 Connell WR, Kamm MA, Ritchie JK et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-1085
• 18 Kennedy NA, Kalla R, Warner B et al. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther 2014; 40: 1313-1323
• 19 Korelitz BI, Fuller SR, Warman JI et al. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 1999; 94: 424-426
• 20 Toruner M, Loftus Jr EV, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936
• 21 Connell WR, Kamm MA, Dickson M et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-1252
• 22 Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625
• 23 Setshedi M, Epstein D, Winter TA et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012; 27: 385-389
• 24 Nørgård B, Pedersen L, Christensen LA et al. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-1413
• 25 Akbari M, Shah S, Velayos FS et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 15-22
• 26 Wluka A, Buchbinder R, Mylvaganam A et al. Longterm methotrexate use in rheumatoid arthritis: 12 year follow up of 460 patients treated in community practice. J Rheumatol 2000; 27: 1864-1871
• 27 Hoekstra M, van de Laar MA, Bernelot Moens HJ et al. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. J Rheumatol 2003; 30: 2325-2329
• 28 Lémann M, Zenjari T, Bouhnik Y et al. Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95: 1730-1734
• 29 Fraser AG, Morton D, McGovern D et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 693-697
• 30 Te HS, Schiano TD, Kuan SF et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 3150-3156
• 31 Griffith SM, Fisher J, Clake S et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?. Rheumatology (Oxford) 2000; 39: 1102-1109
• 32 Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845
• 33 Ogata H, Matsui T, Nakamura M et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-1262
• 34 Ogata H, Kato J, Hirai F et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012; 18: 803-808
• 35 Laharie D, Bourreille A, Branche J et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
• 36 Sternthal MB, Murphy SJ, George J et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 937-943
• 37 Arts J, D‘Haens G, Zeegers M et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-78
• 38 Schmidt KJ, Herrlinger KR, Emmrich J et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis – experience in 130 patients. Aliment Pharmacol Ther 2013; 37: 129-136
• 39 Branche J, Cortot A, Bourreille A et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis 2009; 15: 1044-1048